论文部分内容阅读
目的:探讨临床有效的调脂中药复方的作用机理。方法:给大鼠喂饲高脂饲料4周,造成高脂血症大鼠模型;给药4周后检测各组大鼠血脂、肝细胞高密度脂蛋白(HDL)受体SR-BI基因及蛋白表达、肝细胞低密度脂蛋白(LDL)受体LDLR蛋白表达、肾脏组织中氧化低密度脂蛋白(ox-LDH)受体CD36蛋白表达,并与阿托伐他汀对照。结果:中药组能显著降低实验性高脂血症大鼠的TC、TG、LDL-C水平,与阿托伐他汀组比较无显著性差异(P>0.05);中药组能显著升高高脂血症大鼠的HDL-C水平,与阿托伐他汀组比较有显著差异(P<0.05);中药组及阿托伐他汀组均能下调高脂大鼠肝细胞SR-BI基因表达、上调高脂大鼠肝细胞LDLR蛋白表达、抑制高脂大鼠肾脏组织CD36蛋白表达。结论:中药复方能调节血脂,并在影响血脂代谢的脂蛋白受体基因、蛋白表达水平上,起到多层次、多环节、多靶点调节作用,对血脂异常及动脉粥样硬化(AS)的防治起到重要作用。
Objective: To explore the mechanism of action of traditional Chinese medicine compound prescription of lipid-lowering. Methods: The rats were fed with high-fat diet for 4 weeks, resulting in hyperlipidemic rat model. After 4 weeks of administration, the serum lipids and the gene expression of high density lipoprotein (HDL) receptor SR-BI of hepatocytes LDLR expression of hepatocyte LDL receptor, CD36 protein expression of ox-LDH receptor in renal tissue, and compared with atorvastatin. Results: The traditional Chinese medicine group can significantly reduce the level of TC, TG and LDL-C in experimental hyperlipidemic rats, and no significant difference compared with atorvastatin group (P> 0.05) Compared with atorvastatin group, the level of HDL-C in hyperlipidemic rats was significantly different (P <0.05). Both the traditional Chinese medicine group and atorvastatin group could downregulate the gene expression of SR-BI in hepatocytes in hyperlipidemic rats The expression of LDLR protein in high fat rat liver cells inhibited the expression of CD36 protein in the kidney of high fat diet rats. Conclusion: The Chinese herbal compound can regulate blood lipids and play a multi-level, multi-link and multi-target regulation on lipoprotein receptor gene and protein expression that affect blood lipid metabolism. It has the effect on dyslipidemia and atherosclerosis (AS) Prevention plays an important role.